# CAR-T Therapy Sector Canonical URL: https://biopharmsignal.com/sector/car-t-therapy CAR-T Therapy includes companies engineering chimeric antigen receptor T cells to recognize and kill target cells. This category remains central to hematologic malignancies and is also watched closely for attempts to expand cell therapy into autoimmune disease and solid tumors. Companies currently grouped under CAR-T Therapy: 37 ## Recent Sector News - 2026-07-13 12:00 EST — TCMD — [Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients](https://biopharmsignal.com/news/TCMD/tactile-medical-enters-exclusive-u-s-distribution-agreement-with-elastimed-for-i-116aea64) — Source: Tactile Systems Technology, Inc. - 2026-07-06 12:00 EST — LCTX — [Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-present-at-b-riley-securities-2026-mind-muscle-visi-93d042e3) — Source: Lineage Cell Therapeutics - 2026-06-30 23:56 EST — MESO — [Receives FDA BLA Filing Number and Requests Modular Review](https://biopharmsignal.com/news/MESO/receives-fda-bla-filing-number-and-requests-modular-review-03d96298) — Source: Mesoblast - 2026-06-30 11:30 EST — PSTV — [Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding](https://biopharmsignal.com/news/PSTV/plus-therapeutics-provides-mid-year-business-update-including-corporate-rebrandi-b0939053) — Source: PLUS THERAPEUTICS, Inc. - 2026-06-29 22:13 EST — MESO — [Becoming a substantial holder](https://biopharmsignal.com/news/MESO/becoming-a-substantial-holder-3be3e358) — Source: Mesoblast - 2026-06-28 22:18 EST — MESO — [Ceasing to be a substantial holder](https://biopharmsignal.com/news/MESO/ceasing-to-be-a-substantial-holder-aff3eb75) — Source: Mesoblast - 2026-06-25 13:46 EST — LYEL — [Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-announces-participation-in-h-c-wainwright-4th-annual-cell-therapy-virtual-conference) — Source: Lyell Immunopharma - 2026-06-25 13:46 EST — PSTV — [Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer](https://biopharmsignal.com/news/PSTV/plus-therapeutics-secures-national-coverage-agreement-with-elevance-health-for-cnsider-cerebrospinal-fluid-assay-for-metastatic-cns-cancer) — Source: PLUS THERAPEUTICS, Inc. - 2026-06-25 13:46 EST — MESO — [Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility](https://biopharmsignal.com/news/MESO/mesoblast-draws-us-50m-from-five-year-non-dilutive-facility) — Source: Mesoblast - 2026-06-25 13:46 EST — PSTV — [Plus Therapeutics to Provide Business Update Call on June 30, 2026](https://biopharmsignal.com/news/PSTV/plus-therapeutics-to-provide-business-update-call-on-june-30-2026) — Source: PLUS THERAPEUTICS, Inc. - 2026-06-25 13:46 EST — MESO — [Becoming a substantial holder](https://biopharmsignal.com/news/MESO/becoming-a-substantial-holder) — Source: Mesoblast - 2026-06-25 13:46 EST — LYEL — [Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-presents-updated-safety-data-and-translational-insights-for-rondecabtagene-autoleucel-ronde-cel-in-patients-with-large-b-cell-lymphoma-at-european-hematology-association-2026-congress) — Source: Lyell Immunopharma - 2026-06-25 13:46 EST — MESO — [Ceasing to be a substantial holder](https://biopharmsignal.com/news/MESO/ceasing-to-be-a-substantial-holder) — Source: Mesoblast - 2026-06-25 13:46 EST — LYEL — [Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion) — Source: Lyell Immunopharma - 2026-06-25 13:46 EST — LYEL — [Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress](https://biopharmsignal.com/news/LYEL/lyell-immunopharma-to-present-phase-1-2-safety-and-translational-data-for-ronde-cel-in-large-b-cell-lymphoma-at-the-european-hematology-association-2026-congress) — Source: Lyell Immunopharma - 2026-06-25 13:46 EST — XBIO — [Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma) — Source: Xenetic - 2026-06-25 13:46 EST — PSTV — [Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnsider-diagnostics-clinical-laboratory) — Source: PLUS THERAPEUTICS, Inc. - 2026-06-25 13:46 EST — IOVA — [Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia](https://biopharmsignal.com/news/IOVA/iovance-s-amtagvir-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia) — Source: Iovance Biotherapeutics, Inc. - 2026-06-25 13:46 EST — CABA — [Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-new-rese-cel-data-and-development-updates-across-autoimmune-portfolio-including-encouraging-early-pc-free-lupus-findings-at-eular-2026-congress) — Source: Cabaletta Bio - 2026-06-25 13:46 EST — BCLI — [BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine](https://biopharmsignal.com/news/BCLI/brainstorm-cell-therapeutics-announces-publication-calling-for-updated-fda-approaches-to-als-rare-diseases-and-regenerative-medicine) — Source: Brainstorm Cell Therapeutics Inc. ## Companies - [ADAP](https://biopharmsignal.com/company/ADAP) — Adaptimmune Therapeutics plc - [ALLO](https://biopharmsignal.com/company/ALLO) — Allogene Therapeutics - [AUTL](https://biopharmsignal.com/company/AUTL) — Autolus Therapeutics plc - [BCLI](https://biopharmsignal.com/company/BCLI) — Brainstorm Cell Therapeutics Inc. - [CABA](https://biopharmsignal.com/company/CABA) — Cabaletta Bio - [CRGX](https://biopharmsignal.com/company/CRGX) — CARGO Therapeutics - [RNAC](https://biopharmsignal.com/company/RNAC) — Cartesian Therapeutics - [IPSC](https://biopharmsignal.com/company/IPSC) — Century Therapeutics - [CRSP](https://biopharmsignal.com/company/CRSP) — CRISPR Therapeutics - [GILD](https://biopharmsignal.com/company/GILD) — Gilead Sciences - [GRCL](https://biopharmsignal.com/company/GRCL) — Gracell Biotechnologies - [TIL](https://biopharmsignal.com/company/TIL) — Instil Bio - [IOVA](https://biopharmsignal.com/company/IOVA) — Iovance Biotherapeutics, Inc. - [JNJ](https://biopharmsignal.com/company/JNJ) — Johnson & Johnson - [KYTX](https://biopharmsignal.com/company/KYTX) — Kyverna Therapeutics - [LEGN](https://biopharmsignal.com/company/LEGN) — Legend Biotech Corporation - [LCTX](https://biopharmsignal.com/company/LCTX) — Lineage Cell Therapeutics - [LYEL](https://biopharmsignal.com/company/LYEL) — Lyell Immunopharma - [MESO](https://biopharmsignal.com/company/MESO) — Mesoblast - [NAUT](https://biopharmsignal.com/company/NAUT) — Nautilus Biotechnology - [NKTX](https://biopharmsignal.com/company/NKTX) — Nkarta - [NKGN](https://biopharmsignal.com/company/NKGN) — NKGen Biotech, Inc. - [NVS](https://biopharmsignal.com/company/NVS) — Novartis AG - [OMED](https://biopharmsignal.com/company/OMED) — OncoMed Pharmaceuticals - [PMCB](https://biopharmsignal.com/company/PMCB) — PharmaCyte Biotech - [PSTV](https://biopharmsignal.com/company/PSTV) — PLUS THERAPEUTICS, Inc. - [PGEN](https://biopharmsignal.com/company/PGEN) — Precigen - [PROK](https://biopharmsignal.com/company/PROK) — ProKidney - [QNRX](https://biopharmsignal.com/company/QNRX) — Quoin - [SNY](https://biopharmsignal.com/company/SNY) — Sanofi - [SELB](https://biopharmsignal.com/company/SELB) — Selecta - [SGTX](https://biopharmsignal.com/company/SGTX) — Sigilon Therapeutics - [SQZ](https://biopharmsignal.com/company/SQZ) — SQZ Biotech - [TCMD](https://biopharmsignal.com/company/TCMD) — Tactile Systems Technology, Inc. - [TRML](https://biopharmsignal.com/company/TRML) — Talaris Therapeutics - [VCEL](https://biopharmsignal.com/company/VCEL) — Vericel Corp - [XBIO](https://biopharmsignal.com/company/XBIO) — Xenetic